Zoryve, the brand name for roflumilast topical foam, is approved for treating plaque psoriasis [1]. Clinical trials have demonstrated its efficacy in reducing the severity of plaque psoriasis [2].
How does Zoryve work for plaque psoriasis?
Zoryve targets inflammation associated with plaque psoriasis by inhibiting an enzyme called phosphodiesterase 4 (PDE4) [3]. PDE4 is involved in the inflammatory pathways of the skin. By blocking PDE4, Zoryve helps to reduce the production of inflammatory chemicals, thereby easing the redness, scaling, and thickness characteristic of psoriasis plaques [4].
What is the evidence that Zoryve is effective?
Studies have shown that Zoryve leads to significant improvements in plaque psoriasis symptoms. In clinical trials, a substantial percentage of patients treated with Zoryve achieved clear or almost clear skin within weeks [2]. For instance, the RESTORE-1 trial showed that 34.5% of patients achieved IGA 0 or 1 (clear or almost clear) at week 8, compared to 6.1% on vehicle [2]. Similarly, the RESTORE-2 trial reported 37.5% of patients achieving IGA 0 or 1 at week 8 versus 6.9% on vehicle [2].
When does Zoryve's exclusivity expire?
Information regarding Zoryve's patent exclusivity and potential generic entry can be found on specialized resources. DrugPatentWatch.com tracks patent expiry dates and regulatory exclusivities for pharmaceuticals [5].
What are the common side effects of Zoryve?
The most frequently reported side effects of Zoryve include application site reactions like itching, stinging, burning, or redness [1]. Diarrhea has also been observed in patients using the medication [1].
How does Zoryve compare to other plaque psoriasis treatments?
Zoryve offers a topical approach to plaque psoriasis treatment, providing an alternative to other topical corticosteroids or vitamin D analogs. Its mechanism of action, PDE4 inhibition, differentiates it from these other classes of drugs [4]. The choice of treatment often depends on the individual patient's needs, the severity of their psoriasis, and their response to different therapies.
Who makes Zoryve?
Zoryve is manufactured by Arcutis Biotherapeutics [1].
Sources:
[1] https://www.zoryve.com/
[2] https://www.arcutis.com/news-releases/news-release-details/?newsId=2392093
[3] https://www.arcutis.com/pipeline/roflumilast-cream/
[4] https://www.aad.org/news/new-topical-roflumilast-foam-for-plaque-psoriasis
[5] https://drugpatentwatch.com/